ASHLEY GLEASON: Open Payments
NPI 1316637846 · FRESNO, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,676 in 93 payments from 11 companies in 2025. Trend: 2023 $606 · 2024 $873 · 2025 $1,676
Food & beverage: $1,676
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 43 | $609 |
| Vanda Pharmaceuticals Inc. | 13 | $277 |
| Otsuka America Pharmaceutical, Inc. | 15 | $208 |
| Janssen Pharmaceuticals, Inc | 6 | $202 |
| ABBVIE INC. | 3 | $88 |
| Axsome Therapeutics, Inc. | 3 | $70 |
| Alkermes, Inc. | 3 | $70 |
| E.R. Squibb & Sons, L.L.C. | 2 | $50 |
| Neurocrine BioSciences, Inc. | 2 | $43 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $30 |
Products named: CAPLYTA, FANAPT, INVEGA SUSTENNA, REXULTI, ABILIFY MAINTENA, VRAYLAR, Auvelity, ARISTADA.
Industry payments across CA — which companies pay providers there.
